Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has maintained a Buy rating on Vera Therapeutics and increased the price target from $56 to $64.
October 28, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has reaffirmed its Buy rating on Vera Therapeutics and increased the price target from $56 to $64, indicating confidence in the company's future performance.
The increase in price target from $56 to $64 by Guggenheim suggests a positive outlook on Vera Therapeutics' future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100